RT Journal Article
SR Electronic
T1 THE NEWCASTLE EXPERIENCE OF ANTI-MOG ASSOCIATED DISEASE
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP e1
OP e1
DO 10.1136/jnnp-2016-315106.142
VO 87
IS 12
A1 Bolton, Clare
A1 Chapman, James
A1 Ledingham, David
A1 Lewis-Smith, David
A1 Spyropoulos, Achillefs
A1 Guadagno, Joe
A1 Duddy, Martin
YR 2016
UL http://jnnp.bmj.com/content/87/12/e1.49.abstract
AB The original reports of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies describe a predominant association with acute disseminated encephalomyelitis in children and with neuromyelitis optica spectrum disease (NMOSD) in adults. More recent studies broaden the spectrum of associated disorders to include recurrent optic neuritis and a picture similar to CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids).We performed a retrospective case note review of the presentation, imaging, laboratory findings and response to treatment of a group of 12 patients, aged 3–55 years, with CNS demyelinating disease, who tested positive (out of 117 tests) at a single centre. Our series shows a frequent biphasic pattern of illness. In over 75% there was an acute, often multifocal and highly steroid responsive first phase. In over half this was followed by a second phase, typically single or recurrent episodes of optic neuritis. Adult patients appear more likely to develop limited forms of the disease such as isolated recurrent optic neuritis or monophasic forms, though with significantly adverse outcomes in some cases. This pattern of disease following a suggestive initial presentation may have important implications for guiding both when to test for anti-MOG antibody and decisions on further therapy.